Zydus Lifesciences Posts 22% Revenue Growth as Branded Portfolio Expands
Indian pharmaceutical company reports strong Q1 results with double-digit growth across key segments and advances U.S. specialty platform.
Strong Quarter Across All Segments
Zydus Lifesciences Limited kicked off fiscal 2027 with consolidated revenues of INR 80.2 billion, representing 22% year-on-year growth, the company reported on its August 11 earnings call. The Mumbai-based pharmaceutical firm posted an EBITDA margin of 24.1% and net profit of INR 9.4 billion for the quarter ended June 30, 2026 (earnings call, 2026-08-11).
"We commenced FY '27 with strong double-digit growth, building on the formidable base of FY '26," said Ganesh Nayak, Director at Zydus Lifesciences, attributing the performance to "sustained momentum across all our key businesses" (earnings call, 2026-08-11).
India Business Outpaces Market
The company's Indian Branded Formulations business delivered 20% year-on-year growth during the quarter, continuing a trend of market outperformance over the past three financial years. Growth was broad-based across cardiovascular, dermatology, gynecology, and pain management therapies, with Zydus maintaining its leadership position in oncology (earnings call, 2026-08-11).
The chronic and sub-chronic portfolio now accounts for 54.2% of the Indian business, an improvement of 360 basis points over four years. Managing Director Dr. Sharvil Patel noted that innovative brands, led by Lipaglyn, "continue to strengthen their market standing and improve their rankings quarter after quarter" (earnings call, 2026-08-11).
International Expansion Continues
Zydus's International Markets Formulations business posted revenues of INR 9.7 billion with 34% year-on-year growth, establishing itself as what the company called "a formidable growth pillar." The North America business, comprising the U.S. and Canada, generated INR 31 billion in revenues, up 5% quarter-on-quarter (earnings call, 2026-08-11).
The company achieved two significant U.S. milestones during the quarter: launching Nueno Index, its first biosimilar in the U.S. market, and completing the acquisition of Assertio Holdings to strengthen its specialty commercial capabilities (earnings call, 2026-08-11).
Strategic Shift Toward Branded Portfolio
Dr. Patel emphasized the company's transformation strategy, noting that branded products now account for over 55% of total revenue in Q1. "As our branded business continues to gain scale across markets, we expect their share to exceed 2/3 of our overall revenue over the near term," he stated (earnings call, 2026-08-11).
The U.S. branded business now contributes 10% of American revenues, with expectations to exceed 15% by year-end. Growth drivers include the orphan and rare disease franchise, a portfolio of 52 products, and an NDA submission for saroglitazar, the company's first internally developed innovation for the U.S. market (earnings call, 2026-08-11).
Consumer and Innovation Progress
The Consumer Wellness business recorded revenues of INR 14.3 billion, up 67% year-on-year, with international business delivering 25% like-to-like growth. Skin and hair care segments grew 35%, while Food & Nutrition expanded 16% (earnings call, 2026-08-11).
On the innovation front, the U.S. FDA granted priority review to the company's new drug application for primary biliary cholangitis treatment. Zydus also received regulatory approval in India to initiate Phase III trials of desidustat for sickle cell disease, representing "a potentially first-in-class therapeutic opportunity" (earnings call, 2026-08-11).
The company maintained a net debt-to-EBITDA ratio of 0.7x as of June 30, 2026, according to MarginX data.
This article was generated by MarginX from the earnings call on 2026-08-11. It is not investment advice.